Hiroshi Miyamoto
Hiroshi宫本茂,医学博士,完成了他的医学chool and urology residency training followed by clinical urology practice and translational research in genitourinary cancers in Japan. In 1996, he moved to the United States to conduct postdoctoral research at University of Wisconsin - Madison and University of Rochester. He then completed anatomic pathology residency training at University of Rochester Medical Center and clinical fellowship in urologic pathology at The Johns Hopkins Hospital. Since 2009, he has been the faculty as a surgical pathologist as well as an independent investigator at University of Rochester School of Medicine and Dentistry (2009-2013 & 2016-present) and Johns Hopkins University School of Medicine (2013-2016). He is currently the Professor of Pathology & Laboratory Medicine, Urology, and Oncology, and also serves as the Director of Genitourinary Pathology at University of Rochester Medical Center.
宫本茂博士的主要研究兴趣包括molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signals in the development and progression of urothelial cancer as well as resistance to conventional therapy for bladder cancer. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, whereas women tend to present with more aggressive tumors. The underlying mechanisms of how androgens regulate urothelial tumorigenesis and tumor outgrowth will offer explanations for these gender-specific differences in cancer incidence and aggressiveness. He has also assessed the effects of new classes of androgen receptor antagonists on prostate cancer progression and has characterized novel androgen receptor co-regulators in prostate cancer cells. He has published more than 200 peer-reviewed articles and 17 book chapters.
Hiroshi Miyamoto
Hiroshi宫本茂,医学博士,完成了他的医学chool and urology residency training followed by clinical urology practice and translational research in genitourinary cancers in Japan. In 1996, he moved to the United States to conduct postdoctoral research at University of Wisconsin - Madison and University of Rochester. He then completed anatomic pathology residency training at University of Rochester Medical Center and clinical fellowship in urologic pathology at The Johns Hopkins Hospital. Since 2009, he has been the faculty as a surgical pathologist as well as an independent investigator at University of Rochester School of Medicine and Dentistry (2009-2013 & 2016-present) and Johns Hopkins University School of Medicine (2013-2016). He is currently the Director of Genitourinary Pathology at University of Rochester Medical Center.
宫本茂博士的主要研究兴趣包括molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signals in the development and progression of urothelial cancer. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, whereas women tend to present with more aggressive tumors. The underlying mechanisms of how androgens regulate urothelial tumorigenesis and tumor outgrowth will offer explanations for these gender-specific differences in cancer incidence and aggressiveness. He has also assessed the effects of new classes of androgen receptor antagonists on prostate cancer progression and has characterized novel androgen receptor co-regulators in prostate cancer cells. He has published more than 160 peer-reviewed articles and 17 book chapters.
External Databases & Indexes
- CAS
- ROAD
- SciCurve Open
- Refseek
- WorldCat
- Crossref
- Google scholar
- Pubmed*
- SciLit
- Electronic Journals Library (EZB)
- German Journal Database (ZDB)
- Scientific Indexing Services (SIS)
- Publons
All published articles are provided with DOI and are permanently archived at Open Access Text website in PDF and HTML formats.
* Pubmed:只有selected publications will be indexed.
Submit Manuscript
Integrative Cancer Science and Therapeutics welcomes direct submissions of manuscripts from authors. You can submit your manuscript to:submissions@oatext.com; alternatively to:editor.icst@oatext.com
Publication Charges
Integrative Cancer Science and Therapeutics是一个开放存取期刊,我们不负责吗end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.
//
The publication charges for Integrative Cancer Science and Therapeutics are USD 1990.
Frequently Asked Questions (FAQs)
Why are your charges set at these levels?
所有的文章发表在OA文本是开放获取。Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.
Our financial goals are to:
- Recover capitalization costs;
- Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
- Bend the publication-charge cost downward over time.
Who will pay the APC?
Corresponding author or Co-authors has to make the payment on acceptance of the article.
When should I pay?
Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.
*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.
How do I pay?
Authors or institutions can make payments by two modes as per their convenience.
- Wire/Bank transfer
- Card payment
Note:No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.
Can I be eligible for wavier on APC?
The waiver request will be considered on a case-by-case basis, and will be provided accordingly.
*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.
Do I have to pay if my manuscript is rejected?
No, Article processing charges will not be applicable for articles rejected by the Editorial office.
Withdrawal Charges
Are reprints of my article included in the article processing charges (APCs)?
No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.
Special Issues
Lung Cancer
Editor Affiliation:
Kazuya Fukuoka, MD, PhD,
Department of Medical Oncology
Sakai Hospital, Kinki University Faculty of Medicine
Japan
Submission date: December 15, 2019
Publication date: January 10, 2020
Description of the Special Issue: The special issue focuses on all areas of lung cancer from basic biology to advanced treatment, prevention, epidemiology and etiology. Original articles, research, reviews, mini reviews, cases, commentaries, short communications, letters, opinions are accepted for publication.
Submit manuscript to:editor.icst@oatext.com
Breast cancer
Editor Affiliation:
Masakazu Toi, M.D. Ph.D,
Professor
Breast Surgery, Kyoto University
Japan
Submission date: December 10, 2019
Publication date: January 15, 2020
Description of the Special Issue: The special issue is interested in all areas of biology and medicine related to breast cancer, including basic biology, genetics, causes, diagnosis, treatment etc., with focus on latest advances in breast cancer therapy. All types of articles are accepted for publication.
Submit manuscript to:editor.icst@oatext.com
Brain tumor
Editor Affiliation:
Damir Nizamutdinov
Associate Director of Neuro-Oncology Research
Department of Neurosurgery
Baylor Scott and White Health
Assistant Professor of Surgery
Texas A&M University
USA
Ekokobe Fonkem
Neuro-Oncologist
Baylor Scott & White Health
USA
Submission date: December 20, 2019
Publication date: January 16, 2020
Description of the Special Issue: The special issue accepts articles on all aspects related to the research in brain tumor and neuro oncology. Clinical and experimental results in tumor pathology, reviews, case reports on brain tumor, short communications, opinions, commentaries etc., are welcome for publication under this section.
Submit manuscript to:editor.icst@oatext.com
Cancer Surgery
Editor Affiliation:
Johnson Miller Denise
Director
Hackensack Meridian Health
NJ, USA
Submission date: December 10, 2019
Publication date: January 15, 2020
The special issue focus on the surgical treatment of different cancer types like Breast Cancer, Lung Cancer, Kidney Cancer, Gastro intestinal cancer, gynaecological cancer, Thyroid Cancer, Prostate Cancer, neuro oncology, etc. All types of articles along with surgical images are suitable for publication.
Submit manuscript to:editor.icst@oatext.com
Hiroshi宫本茂,医学博士,完成了他的医学chool and urology residency training followed by clinical urology practice and translational research in genitourinary cancers in Japan. In 1996, he moved to the United States to conduct postdoctoral research at University of Wisconsin - Madison and University of Rochester. He then completed anatomic pathology residency training at University of Rochester Medical Center and clinical fellowship in urologic pathology at The Johns Hopkins Hospital. Since 2009, he has been the faculty as a surgical pathologist as well as an independent investigator at University of Rochester School of Medicine and Dentistry (2009-2013 & 2016-present) and Johns Hopkins University School of Medicine (2013-2016). He is currently the Professor of Pathology & Laboratory Medicine, Urology, and Oncology, and also serves as the Director of Genitourinary Pathology at University of Rochester Medical Center.